A multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours.

Brennan, PM.; Cameron, JM.; Eustace, D.; Butler, HJ.; Sala, A.; Lazarus, A.; Antoniou, G.; Palmer, DS.; Gray, E.; Kerrie, C.; McDonald, S.; Black, P.; Sheraz, S.; Adekoya, I.; Jakola, A.; Denes, A.; Jenkinson, MD.; Jones, J.; Pendered, S.; Koljenovic, S.; Zwaenepoel, K.; Sieben, A.; Ahmed, M.; Feyen, B.; Mathew, RK.; Coils, C.; Ismail, A.; Phang, I.; Brown, A.; Patel, S.; Weiss, T.; Westarp, PW.; Kopp, A.; Baker, MJ.

A multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours.

All Authors

Brennan, PM.

Cameron, JM.

Eustace, D.

Butler, HJ.

Sala, A.

Lazarus, A.

Antoniou, G.

Palmer, DS.

Gray, E.

Kerrie, C.

Show 10 more

LTHT Author

Mathew, Ryan
Coils, Casey

LTHT Department

Neurosciences
Neurosurgery
Complex Rehabilitation

Non Medic

Sister

Publication Date

2025

Item Type

Journal Article

Abstract

BACKGROUND: Delayed diagnosis of brain cancer leads to two-thirds of patients receiving a diagnosis only after presenting to the emergency department with more severe symptoms or neurological deficits. A simple, rapid, liquid biopsy implemented in primary care could enable more efficient triage of patients with non-specific symptoms potentially related to brain cancer, prioritising patients for urgent brain imaging, and accelerating diagnosis. PATIENTS AND METHODS: Presented is the international, multi-centre, observational Early and tiMely detection of BRAin CancEr (EMBRACE) study. Patients were prospectively recruited across seven sites in Europe, from the United Kingdom, Belgium, Sweden and Switzerland. The target population consisted of patients with symptoms potentially associated with brain cancer. Blood serum samples were analysed by the Dxcover R Brain Cancer Liquid Biopsy Platform. Test performance was assessed by comparison of the liquid biopsy result to diagnostic imaging. RESULTS: Two thousand five hundred and fifty-four patients were enrolled across the seven collection sites; 2324 were deemed eligible and taken forward for test assessment. There were 697 brain tumours in total, of which 395 were malignant, and 1627 non-tumour diagnoses. Overall diagnostic performance for the primary objective was 86% sensitivity for brain cancer detection with 99% negative predictive value (NPV). Sensitivity for all brain tumours combined (malignant and benign) was 77%. Notably, for the most prevalent and most aggressive brain cancer, glioblastoma, 86% of cases were successfully identified. Additionally, 94% of patients with central nervous system lymphoma, and 90% of brain metastases were predicted correctly as having tumours. CONCLUSIONS: Existing symptom-based referral pathways are ineffective for the detection of brain cancer, and there is an urgent need for new tests to help with clinical decision making. With a NPV of 99%, the Dxcover Liquid Biopsy test could assist in primary care for efficient stratification of patients toward diagnostic imaging.